Pediatr Crit Care Me
-
Pediatr Crit Care Me · Sep 2014
Editorial CommentSerum biomarkers of brain injury: a call for collaboration*.
-
Pediatr Crit Care Me · Sep 2014
ReviewUnderstanding the Global Epidemiology of Pediatric Critical Illness: The Power, Pitfalls, and Practicalities of Point Prevalence Studies.
The point prevalence methodology is a valuable epidemiological study design that can optimize patient enrollment, prospectively gather individual-level data, and measure practice variability across a large number of geographic regions and healthcare settings. The objective of this article is to review the design, implementation, and analysis of recent point prevalence studies investigating the global epidemiology of pediatric critical illness. ⋯ Point prevalence studies in pediatric critical care can efficiently provide valuable insight on the global epidemiology of disease and practice patterns for critically ill children.
-
Pediatr Crit Care Me · Sep 2014
Higher Doses of Low-Molecular-Weight Heparin (Enoxaparin) Are Needed to Achieve Target Anti-Xa Concentrations in Critically Ill Children.
To demonstrate that low-molecular-weight heparin (enoxaparin) can be used in critically ill pediatric patients to achieve target anti-factor Xa concentrations and determine appropriate dosing corrected for age and illness severity. ⋯ Enoxaparin can be used to reach recommended target range of anti-factor Xa concentrations in the PICU patient. However, younger patients and patients with higher illness severity are less likely to achieve target concentrations using currently recommended dosing and may require higher doses of enoxaparin to reach target anti-factor Xa concentrations. Starting enoxaparin dose at least 1.3 mg/kg dosed every 12 hours for treatment of thromboembolic disease in critically ill patients aged 61 days to 1 year or those requiring inotropic support should be confirmed in prospective study.